Hainan Shuangcheng Pharmaceuticals Co Ltd banner

Hainan Shuangcheng Pharmaceuticals Co Ltd
SZSE:002693

Watchlist Manager
Hainan Shuangcheng Pharmaceuticals Co Ltd Logo
Hainan Shuangcheng Pharmaceuticals Co Ltd
SZSE:002693
Watchlist
Price: 8.61 CNY -3.26% Market Closed
Market Cap: ¥3.6B

EV/EBITDA

-85.1
Current
6%
More Expensive
vs 3-y average of -80.1

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
-85.1
=
Enterprise Value
¥3.3B
/
EBITDA
¥-43.4m

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
-85.1
=
Enterprise Value
¥3.3B
/
EBITDA
¥-43.4m

Valuation Scenarios

Hainan Shuangcheng Pharmaceuticals Co Ltd is trading above its industry average

If EV/EBITDA returns to its Industry Average (23.9), the stock would be worth ¥-2.42 (128% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-134%
Maximum Upside
No Upside Scenarios
Average Downside
131%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple -85.1 ¥8.61
0%
Industry Average 23.9 ¥-2.42
-128%
Country Average 28.8 ¥-2.92
-134%

Forward EV/EBITDA
Today’s price vs future ebitda

Not enough data available to calculate forward EV/EBITDA

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
CN
Hainan Shuangcheng Pharmaceuticals Co Ltd
SZSE:002693
3.6B CNY -85.1 -83.1
US
Eli Lilly and Co
NYSE:LLY
835.2B USD 27.4 40.5
US
Johnson & Johnson
NYSE:JNJ
547.8B USD 16.7 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 11.9 20.1
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 15.6 28
CH
Novartis AG
SIX:NOVN
223.1B CHF 12.1 19.5
US
Merck & Co Inc
NYSE:MRK
276.9B USD 9.5 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 386.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 8.4 11.4
US
Pfizer Inc
NYSE:PFE
153.5B USD 7.6 19.8
US
Bristol-Myers Squibb Co
NYSE:BMY
118.2B USD 7.2 16.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Hainan Shuangcheng Pharmaceuticals Co Ltd
SZSE:002693
Average EV/EBITDA: 50.3
Negative Multiple: -85.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
27.4
21%
1.3
US
Johnson & Johnson
NYSE:JNJ
16.7
8%
2.1
CH
Roche Holding AG
SIX:ROG
11.9
6%
2
UK
AstraZeneca PLC
LSE:AZN
15.6
12%
1.3
CH
Novartis AG
SIX:NOVN
12.1
5%
2.4
US
Merck & Co Inc
NYSE:MRK
9.5
4%
2.4
IE
E
Endo International PLC
LSE:0Y5F
386.8
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.4
2%
4.2
US
Pfizer Inc
NYSE:PFE
7.6
-8%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.2
-9%
N/A
P/E Multiple
Earnings Growth PEG
CN
Hainan Shuangcheng Pharmaceuticals Co Ltd
SZSE:002693
Average P/E: 21.9
Negative Multiple: -83.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.5
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.8
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1

Market Distribution

Lower than 100% of companies in China
Percentile
0th
Based on 5 409 companies
0th percentile
-85.1
Low
0 — 16.3
Typical Range
16.3 — 53.1
High
53.1 —
Distribution Statistics
China
Min 0
30th Percentile 16.3
Median 28.8
70th Percentile 53.1
Max 49 021

Hainan Shuangcheng Pharmaceuticals Co Ltd
Glance View

Market Cap
3.6B CNY
Industry
Pharmaceuticals

Hainan Shuangcheng Pharmaceuticals Co Ltd is a compelling narrative of strategic growth rooted in the heart of China's expanding healthcare landscape. Founded amid the tropical allure of Hainan Province, the company has meticulously carved its niche in the pharmaceutical industry, focusing on the development, manufacture, and distribution of a diverse range of healthcare products. Its operations encompass the creation of traditional Chinese medicines, nutraceuticals, and essential drugs that cater to a wide spectrum of therapeutic needs in the market. By leveraging its rich heritage in Chinese herbal medicine, coupled with modern manufacturing techniques, Shuangcheng has cultivated an innovative portfolio that addresses both contemporary health challenges and traditional wellness aspirations. The company generates revenue primarily through its comprehensive product lineup sold across various distribution channels, including hospitals, pharmacies, and third-party distributors throughout China. With a strategic eye on quality and efficacy, Shuangcheng ensures that its products meet rigorous health standards, thereby building trust and credibility among both healthcare professionals and consumers. This dedication to excellence is bolstered by significant investments in research and development, allowing the firm to potentially evolve with changing medical demands and regulatory landscapes. As the healthcare sector grows within China, Hainan Shuangcheng Pharmaceuticals stands poised at the intersection of modern medicine and traditional wisdom, offering solutions that resonate with the needs of its diverse clientele and ensuring a robust financial performance.

Intrinsic Value
2.02 CNY
Overvaluation 77%
Intrinsic Value
Price ¥8.61
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett